Latest Insider Transactions at Spring Works Therapeutics, Inc. (SWTX)
This section provides a real-time view of insider transactions for Spring Works Therapeutics, Inc. (SWTX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of SpringWorks Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of SpringWorks Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 01
2024
|
James Cassidy Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
591
-0.77%
|
$22,458
$38.53 P/Share
|
|
Jun 03
2024
|
Badreddin Edris Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
20,000
-1.9%
|
$800,000
$40.86 P/Share
|
|
Jun 03
2024
|
Julie Hambleton Director |
SELL
Open market or private sale
|
Direct |
4,648
-16.4%
|
$185,920
$40.89 P/Share
|
|
Jun 03
2024
|
Saqib Islam Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
49,000
-1.07%
|
$1,960,000
$40.87 P/Share
|
|
May 16
2024
|
Freda C Lewis Hall Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,095
+21.83%
|
-
|
|
May 16
2024
|
Daniel Lynch Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,095
+1.32%
|
-
|
|
May 16
2024
|
Carlos Alban Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,095
+17.89%
|
-
|
|
May 16
2024
|
Alan Fuhrman Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,095
+21.83%
|
-
|
|
May 16
2024
|
Julie Hambleton Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,095
+31.9%
|
-
|
|
Apr 01
2024
|
Bhavesh Ashar Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,824
-3.14%
|
$85,728
$47.62 P/Share
|
|
Feb 16
2024
|
Daniel Pichl Chief People Officer |
SELL
Open market or private sale
|
Direct |
15,000
-24.91%
|
$750,000
$50.1 P/Share
|
|
Feb 16
2024
|
Daniel Pichl Chief People Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+19.94%
|
$405,000
$27.64 P/Share
|
|
Feb 05
2024
|
Bhavesh Ashar Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
4,834
-7.67%
|
$236,866
$49.32 P/Share
|
|
Feb 02
2024
|
Bhavesh Ashar Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
3,222
-1.23%
|
$144,990
$45.11 P/Share
|
|
Feb 02
2024
|
Daniel Pichl Chief People Officer |
SELL
Open market or private sale
|
Direct |
26,181
-10.39%
|
$1,178,145
$45.13 P/Share
|
|
Feb 02
2024
|
Daniel Pichl Chief People Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
16,250
+18.54%
|
$438,750
$27.64 P/Share
|
|
Jan 08
2024
|
Michael Nofi Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,063
-3.57%
|
$43,583
$41.53 P/Share
|
|
Jan 08
2024
|
Perier I Francis Jr Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,215
-5.15%
|
$131,815
$41.53 P/Share
|
|
Jan 08
2024
|
Daniel Pichl Chief People Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,405
-2.48%
|
$57,605
$41.53 P/Share
|
|
Jan 08
2024
|
Saqib Islam Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
17,904
-6.53%
|
$734,064
$41.53 P/Share
|
|
Jan 08
2024
|
L. Mary Smith Chief Development Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,535
-1.49%
|
$144,935
$41.53 P/Share
|
|
Jan 08
2024
|
Herschel S Weinstein General Counsel & Secretary |
SELL
Payment of exercise price or tax liability
|
Direct |
2,423
-4.43%
|
$99,343
$41.53 P/Share
|
|
Jan 08
2024
|
Bhavesh Ashar Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,449
-2.14%
|
$59,409
$41.53 P/Share
|
|
Jan 08
2024
|
James Cassidy Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,093
-1.41%
|
$44,813
$41.53 P/Share
|
|
Jan 08
2024
|
Badreddin Edris Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,466
-1.99%
|
$224,106
$41.53 P/Share
|
|
Jan 05
2024
|
Michael Nofi Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,169
-3.78%
|
$43,253
$37.96 P/Share
|
|
Jan 05
2024
|
Perier I Francis Jr Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,151
-3.33%
|
$79,587
$37.96 P/Share
|
|
Jan 05
2024
|
Daniel Pichl Chief People Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,574
-2.71%
|
$58,238
$37.96 P/Share
|
|
Jan 05
2024
|
Saqib Islam Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
12,885
-4.49%
|
$476,745
$37.96 P/Share
|
|
Jan 05
2024
|
L. Mary Smith Chief Development Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,197
-0.92%
|
$81,289
$37.96 P/Share
|
|
Jan 05
2024
|
Herschel S Weinstein General Counsel & Secretary |
SELL
Payment of exercise price or tax liability
|
Direct |
2,324
-4.08%
|
$85,988
$37.96 P/Share
|
|
Jan 05
2024
|
Bhavesh Ashar Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,507
-3.57%
|
$92,759
$37.96 P/Share
|
|
Jan 05
2024
|
James Cassidy Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,357
-2.95%
|
$87,209
$37.96 P/Share
|
|
Jan 05
2024
|
Badreddin Edris Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,469
-1.6%
|
$165,353
$37.96 P/Share
|
|
Jan 04
2024
|
Tai An Lin Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,289
+15.3%
|
-
|
|
Jan 04
2024
|
Michael Nofi Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
14,104
+31.3%
|
-
|
|
Jan 04
2024
|
Perier I Francis Jr Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
21,156
+24.66%
|
-
|
|
Jan 04
2024
|
Daniel Pichl Chief People Officer |
BUY
Grant, award, or other acquisition
|
Direct |
22,919
+28.28%
|
-
|
|
Jan 04
2024
|
Saqib Islam Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
88,000
+23.46%
|
-
|
|
Jan 04
2024
|
L. Mary Smith Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
21,156
+8.13%
|
-
|
|
Jan 04
2024
|
Herschel S Weinstein General Counsel & Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
21,156
+27.07%
|
-
|
|
Jan 04
2024
|
Bhavesh Ashar Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
26,445
+27.37%
|
-
|
|
Jan 04
2024
|
James Cassidy Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
28,208
+26.1%
|
-
|
|
Jan 04
2024
|
Badreddin Edris Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
42,312
+13.15%
|
-
|
|
Nov 30
2023
|
Saqib Islam Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
199,053
+50.0%
|
-
|
|
Oct 02
2023
|
Tai An Lin Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
24,000
+50.0%
|
-
|
|
Sep 01
2023
|
James Cassidy Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,292
-2.44%
|
$38,760
$30.33 P/Share
|
|
Jul 19
2023
|
Julie Hambleton Director |
SELL
Open market or private sale
|
Direct |
2,418
-34.22%
|
$70,122
$29.31 P/Share
|
|
Jun 30
2023
|
L. Mary Smith Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,720
+2.56%
|
-
|
|
Jun 30
2023
|
James Cassidy Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,720
+9.75%
|
-
|